Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated tar ...
A third option is suppression: the United States would forgo development of ASI and stop anyone else from building it on the basis that superintelligence is just too dangerous to be unleashed on the ...
Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...
Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Jack Clark, Anthropic’s co-founder, left on paternity leave last November. When he returned in February, he was surprised to ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results